Farnesyl transferase inhibitors--a novel therapy for breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Farnesyl protein transferase inhibitors (FTIs) were initially developed to block Ras protein signaling in cancer.
• Ras protein post-translational modification is a key step in cell signaling pathways.

Purpose of the Study:

• To review the rationale for FTI development.
• To explore FTIs as a therapeutic strategy for breast cancer, including tumors without Ras mutations.
• To present preclinical data and preliminary Phase II study results in advanced breast cancer.

Main Methods:

• Review of preclinical data in breast cancer models.
• Analysis of preliminary results from a Phase II clinical study of an FTI in advanced breast cancer.

Main Results:

• FTIs impact on cancer cells extends beyond Ras-transformed cells.
• Preclinical data supports FTI efficacy in breast cancer models.
• Phase II study provides preliminary evidence for FTI activity in advanced breast cancer.

Conclusions:

• FTIs represent a potential therapeutic approach for breast cancer, irrespective of Ras mutation status.
• Further investigation into FTIs for breast cancer treatment is warranted based on early findings.